Leadership Overview
Indivior has 5 executives leading key functions including finance, legal, and divisional leadership.
Driven by a mission to treat opioid use disorder, Indivior is dedicated to developing and distributing life-saving medications, impacting global health through pharmaceutical innovation and a commitment to patient recovery.
Driven by a mission to treat opioid use disorder, Indivior is dedicated to developing and distributing life-saving medications, impacting global health through pharmaceutical innovation and a commitment to patient recovery.
Leadership Roles at Indivior
Ryan Preblick - Chief Financial Officer
Ryan Preblick, the Chief Financial Officer at Indivior, directs the company's financial strategy and operations. Preblick oversees all aspects of financial planning, accounting, and investor relations, ensuring fiscal responsibility and driving sustainable growth. This leadership role involves managing capital allocation and optimizing financial performance across global markets. By analyzing market trends and financial data, Preblick guides strategic investment decisions. The Chief Financial Officer ensures compliance with financial regulations and enhances shareholder value. Ryan Preblick's expertise is critical in navigating the complex financial landscape of the pharmaceutical industry, supporting Indivior's mission to combat opioid dependence.
Scott Reents - Executive Vice President & Chief Financial Officer
Scott Reents, the Executive Vice President & Chief Financial Officer at Indivior, manages the company's comprehensive financial framework. Reents is responsible for financial reporting, treasury functions, and risk management, ensuring the integrity and efficiency of all financial activities. This executive role involves collaborating with divisional leaders to align financial objectives with strategic goals. By implementing robust financial controls, Scott Reents supports the development and commercialization of vital treatments for opioid use disorder. The Executive Vice President & Chief Financial Officer plays a crucial part in resource allocation and long-term financial planning, underpinning Indivior's global operations and market expansion. Reents' leadership ensures financial stability and supports the company's commitment to patient access.
Bal Chopra - Segment Chief Financial Officer & Senior VP, Finance, Operations (US)
Bal Chopra, the Segment Chief Financial Officer & Senior VP, Finance, Operations (US) at Indivior, leads financial strategy and operational finance for the US segment. Chopra oversees financial planning, analysis, and reporting, ensuring alignment with Indivior's broader corporate objectives. This critical role involves managing budgets, optimizing operational expenditures, and driving financial performance within the United States market. By providing strategic financial insights, Bal Chopra supports the expansion of critical treatments for opioid use disorder and other CNS disorders. The Segment Chief Financial Officer & Senior VP, Finance, Operations (US) ensures efficient resource deployment and supports key business initiatives. Chopra's financial acumen is vital for sustaining Indivior's operational excellence and market presence in the US.
Matthew Ruth - President, Overdose Reversal Sciences Division
Matthew Ruth, the President, Overdose Reversal Sciences Division at Indivior, spearheads the strategic direction and operational execution for overdose reversal therapies. Ruth drives the development, commercialization, and market access strategies for critical overdose rescue products. This leadership role involves fostering innovation and ensuring the widespread availability of life-saving interventions. By leading cross-functional teams, Matthew Ruth advances Indivior's commitment to combating the opioid crisis. The President, Overdose Reversal Sciences Division oversees research, clinical development, and market penetration for this vital therapeutic area. Ruth's focus is on expanding access and impact, reinforcing Indivior's position as a leader in addiction treatment and overdose prevention.
Jeffrey Burris - Chief Legal Officer
Jeffrey Burris, the Chief Legal Officer at Indivior, directs all legal affairs and corporate governance for the organization. Burris oversees regulatory compliance, intellectual property management, and litigation, safeguarding the company's interests worldwide. This executive position involves advising senior leadership on legal implications of business strategies and ensuring adherence to global pharmaceutical regulations. By managing legal risks, Jeffrey Burris supports the development and distribution of Indivior's life-saving medications. The Chief Legal Officer ensures that all operations align with ethical standards and legal frameworks, protecting the company's reputation and assets. Burris's legal expertise is fundamental to Indivior's mission of improving patient outcomes.
Explore Leadership Teams in Manufacturing
Cambrex is a leading global contract development and manufacturing organization (CDMO) that provides drug substance, drug product, and analytical services across the entire drug lifecycle. With over 40 years of experience and a growing team of experts servicing global clients from North America and Europe, Cambrex is a trusted partner in branded and generic markets for API and finished dosage form development and manufacturing. Cambrex offers a range of specialized drug substance technologies and capabilities, including continuous flow, controlled substances, solid-state science, material characterization, stability storage, and highly potent APIs. In addition, Cambrex can support conventional dosage forms, including oral solids, semi-solids, and liquids, and has the expertise to manufacture specialty dosage forms such as modified-release, fixed-dose combination, pediatric, bi-layer tablets, stick packs, topicals, controlled substances, sterile, and non-sterile ointments.
Company Leadership
RG
Genomma Lab Internacional is a leading provider of innovative health and personal care products aimed at enhancing health and well-being. The company offers a wide range of solutions for various health issues, including hydration, pain relief, and skincare. Its intended clients include individuals seeking effective and safe products to improve their quality of life. Genomma Lab is committed to sustainability and positively impacting communities while ensuring the satisfaction of its shareholders.
Company Leadership MS
MG
GC
RA
TriRx Pharmaceuticals is a contract development and manufacturing organization specializing in both non-sterile and sterile products, including animal health injectables and packaging solutions. The company offers a wide range of capabilities such as development and analytics, sterile and non-sterile manufacturing, and packaging services. With facilities located in Huntsville, Alabama, and Segré, France, TriRx aims to support customers' commercialization efforts across global markets. Their target clients include pharmaceutical companies looking for advanced solutions to bring their products to market.
Company Leadership RM
KL
JS
SH
Eurofarma is a pharmaceutical company that offers a diverse range of products including prescription medications, generics, oncology treatments, hospital care products, personal care items, and nutritional supplements. Their services are aimed at healthcare professionals, consumers, pharmacies, and B2B clients across various countries in Latin America. The company is committed to sustainability and innovation, actively engaging in clinical research and development. With over 50 years in the industry, Eurofarma focuses on improving health and wellness while maintaining a strong corporate governance framework.
Company Leadership MB
ET
FD
BS
Frequently Asked Questions Regarding Indivior Top Executives and Leadership Team
